摘要
目的:探讨索拉菲尼联合肝动脉灌注对肝癌患者血清VEGF、TR及血糖水平、胰岛素抵抗的影响.方法:选择2018年2月-2019年2月广东省佛山市高明区人民医院肿瘤科肝癌疾病60例作为对象,随机数字法分为联合治疗组、单纯肝动脉化疗组和单纯索拉非尼组,每组各20例.单纯肝动脉化疗组采用肝动脉灌注化疗治疗,单纯索拉非尼组采用口服索拉非尼治疗,联合治疗组采用索拉非尼联合肝动脉灌注治疗,治疗后1个月对患者效果进行评估,比较三组近期疗效、血清VEGF、TR水平、血糖水平、胰岛素抵抗及毒副反应发生情况.结果:单纯肝动脉化疗组、单纯索拉非尼组治疗后1个月VEGF、TR水平比较,差异均无统计学意义(P>0.05);联合治疗组治疗后1个月血清VEGF、TR低于单纯肝动脉化疗组、单纯索拉非尼组(P<0.05).治疗前后比较,联合治疗组血糖控制均更稳定(HbA1c、FBG水平),低血糖发生率降低.联合治疗组胰岛素抵抗与单纯肝动脉化疗组、单纯索拉非尼组比较,有明显改善(P<0.05).三组治疗过程中腹泻、发热、肝区疼痛、低血糖发生率比较,差异均无统计学意义(P>0.05).结论:将索拉菲尼联合肝动脉灌注用于肝癌患者中改善联合治疗组水平,未增加毒副反应发生率,值得推广应用.
Objective:To investigate the effects of Sorafenib combined with hepatic artery perfusion on serum VEGF,TR,blood glucose and insulin resistance in patients with liver cancer.Method:Sixty patients with hepatocellular carcinoma of the Department of Oncology,Gaoming District People’s Hospital,Foshan City,Guangdong Province,from February 2018 to February 2019 were selected as subjects.According the randomized digital method,they were divided into the combined treatment group,the simple hepatic arterial chemotherapy group and the simple Sorafenib group,20 cases in each group.Hepatic arterial infusion chemotherapy was used in the hepatic arterial chemotherapy group,Sorafenib was given in the Sorafenib group alone,the combined treatment group was given Sorafenib combined with hepatic arterial infusion.The patient’s effect was evaluated after treatment 1 month.The short-term efficacy,serum VEGF,TR levels and incidence of toxic side effects were compared between the three groups.Result:There was no significant difference in VEGF and TR levels between the hepatic arterial chemotherapy group and the Sorafenib group(P>0.05).The serum VEGF and TR levels in combined treatment group were lower than those the simple hepatic arterial chemotherapy group and the simple Sorafenib group at 1 month after treatment.The blood glucose control in the combined treatment group was more stable(HbA1c,FBG)and the incidence of hypoglycemia was lower(P<0.05).Compared with the simple hepatic arterial chemotherapy group and the simple sorafenib group,the insulin resistance in the combined treatment group was significantly improved(P<0.05).There were no statistically significant differences in the incidence of diarrhea,fever,liver pain and hypoglycemia among the three groups(P>0.05).Conclusion:The combination of Sorafenib and hepatic artery infusion in patients with liver cancer improves the level of combination therapy,and does not increase the incidence of toxic and side effects.It is worthy of popularization and application.
作者
衷锐
谢建立
冯丽娟
姚娟丽
骆晓敏
ZHONG Rui;XIE Jianli;FENG Lijuan;YAO Juanli;LUO Xiaomin(Beijiao Hospital,Shunde District,Foshan City,Foshan 528311,China;不详)
出处
《中国医学创新》
CAS
2020年第16期9-12,共4页
Medical Innovation of China
基金
2019年佛山市自筹经费类科技计划项目(医学类科技攻关)(1920001001140)。
关键词
索拉菲尼
肝动脉灌注
肝癌患者
血糖水平
胰岛素抵抗
Sorafenib
Hepatic artery perfusion
Liver cancer patients
Blood glucose levels
Insulin resistance
